Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The approval was based on the OASIS clinical trial programme and the SELECT cardiovascular outcomes trial, with the OASIS 4 study showing a mean weight loss of 16.6% at 64 weeks in adults with obesity or overweight, among participants who adhered to treatment
Unlike the other medications studied, tirzepatide targets both GLP-1 and another hormone with related effects called GIP
You can review your options without feeling pushed toward a decision
Appetite suppression remains the primary ongoing effect, which is the desired therapeutic outcome
US$ 20.61
US$ 22.71
US$ 26.84
US$ 28.55
US$ 24.70
